Back to Search
Start Over
Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results
- Source :
- Hematology. 14:315-322
- Publication Year :
- 2009
- Publisher :
- Informa UK Limited, 2009.
-
Abstract
- Deferoxamine (DFO) is an iron chelator used to treat iron overload in patients receiving chronic blood transfusions, and is usually administered as overnight subcutaneous infusions. ISOSFER was a prospective, observational, cross-sectional study conducted in metropolitan France that evaluated patient characteristics, quality of life (QoL), compliance and patient satisfaction with DFO monotherapy. Of 70 patients with either thalassemia, sickle cell disease or myelodysplastic syndromes, 30% were 'satisfied' or 'very satisfied' with DFO. Patients' SF-36 scores were lower than those of the general French population, and lower among patients with comorbidities and those dissatisfied with treatment. Although 72% of patients had good compliance to DFO, 57% reported missing at least one infusion in the previous month, and 82% of patients expressed a preference for oral therapy. These results suggest that QoL is severely compromised in patients receiving DFO, and that compliance is not optimal.
- Subjects :
- Adult
Male
Pediatrics
medicine.medical_specialty
Iron Overload
Thalassemia
Population
Siderophores
Deferoxamine
Patient satisfaction
Quality of life
Humans
Medicine
Blood Transfusion
Prospective Studies
Child
education
Aged
Aged, 80 and over
education.field_of_study
business.industry
Myelodysplastic syndromes
Deferasirox
Transfusion Reaction
Hematology
Middle Aged
medicine.disease
Hematologic Diseases
Chelation Therapy
Cross-Sectional Studies
Quality of Life
Patient Compliance
Female
Observational study
France
business
medicine.drug
Subjects
Details
- ISSN :
- 16078454
- Volume :
- 14
- Database :
- OpenAIRE
- Journal :
- Hematology
- Accession number :
- edsair.doi.dedup.....12a26154ce87ad6b67d0110b4b2a690f